21 ноября, 18:08

United Therapeutics PAH Drug's Exclusivity Period Extended

United Therapeutics' PAH drug, Adcirca has been granted six months pediatric exclusivity. This will delay generic competition for the drug for an additional six months.

14 ноября, 01:18

Biotech ETFs: What Lies Ahead?

It's been a good year for biotech ETFs, can the rally continue?

08 ноября, 00:47

What Lies in Store for Pharma ETFs?

Pharma stocks have done well this year; what lies ahead?

Выбор редакции
13 октября, 20:40

What Factors Will Drive Johnson & Johnson's Q3 Earnings?

Johnson & Johnson will report its Q3 2017 earnings on October 17, and we expect the company to post solid numbers, owing to three primary factors – a ramp up in key oncology drug sales, the Actelion acquisition, and forex gains.

12 октября, 17:50

J&J (JNJ) to Kickstart Pharma Q3 Earnings: What's in Store?

J&J's (JNJ) sales and earnings growth are expected to accelerate in third and fourth quarters. The company expects organic sales growth of 4% in the second half of the year.

05 октября, 23:37

4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3

The Large Cap Pharmaceuticals industry has gained 20.7% year to date, outpacing 14.7% gain for the S&P 500.

29 сентября, 16:28

How Will Trump's Proposed Tax Reform Impact Drug Companies?

Donald Trump has proposed new tax reforms for individuals and corporates. Let's see how the reforms, if passed, will impact pharma companies.

28 сентября, 14:12

The Zacks Analyst Blog Highlights: Goldman Sachs Group, PepsiCo, Johnson & Johnson, Cummins and Fidelity National Information Services

The Zacks Analyst Blog Highlights: Goldman Sachs Group, PepsiCo, Johnson & Johnson, Cummins and Fidelity National Information Services

27 сентября, 21:07

Top Stock Reports for Goldman Sachs, PepsiCo and Johnson & Johnson

Top Stock Reports for Goldman Sachs, PepsiCo and Johnson & Johnson

28 июля, 17:57

United Therapeutics (UTHR) Incurs Loss in Q2, Sales Top

United Therapeutics Corporation (UTHR) incurred a loss in Q2. However, stronger sales across the PAH franchise pulled up the top line in the quarter.

21 июля, 16:30

The Zacks Analyst Blog Highlights: Johnson & Johnson, Coca-Cola, Honeywell, Crown Castle and WEC Energy

The Zacks Analyst Blog Highlights: Johnson & Johnson, Coca-Cola, Honeywell, Crown Castle and WEC Energy

18 июля, 16:49

J&J (JNJ) Beats on Q2 Earnings, Lags Sales, Ups 2017 View

Johnson & Johnson (JNJ) reported mixed second-quarter 2017 results. While earnings beat expectations, sales missed the same.

14 июля, 14:28

Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co.

Novartis (NVS) was in the limelight this week with its CAR-T cell therapy receiving the support of an FDA advisory panel.

12 июля, 15:30

J&J (JNJ) to Commence Pharma Q2 Earnings Season: What's Up?

Johnson & Johnson (JNJ), a healthcare bellwether, will report second-quarter 2017 results on Jul 18.

11 июля, 17:51

Arena's Ralinepag Positive in Phase II PAH Study, Shares Up

Arena Pharmaceuticals, Inc. (ARNA) shares surged 41.3% in after-market trading on Monday after its phase II study evaluating its key pipeline candidate, ralinepag, in pulmonary arterial hypertension, met the primary endpoint.

04 июля, 16:16

Cardiome's Partner SteadyMed Submits NDA for PAH Injection

Cardiome Pharma Corp. (CRME) announced that its partner SteadyMed Ltd. (STDY) has submitted a new drug application (NDA) to the FDA for its lead candidate, Trevyent (treprostinil injection), for treatment of pulmonary arterial hypertension (PAH).

30 июня, 18:55

Arena Ends Study on Extended Release Formulation of PAH Drug

Arena Pharmaceuticals, Inc. (ARNA), announced that it has completed an early-stage study comparing the once-daily, extended release (XR) formulation of its experimental pulmonary arterial hypertension (PAH) candidate, ralinepag, with its twice-daily immediate release (IR) formulation.

29 июня, 22:53

M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks

M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks

29 июня, 16:30

Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

28 июня, 22:11

Better Days Ahead for the Pharma Sector?

Better Days Ahead for the Pharma Sector?